SV2017005549A - Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap) - Google Patents

Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap)

Info

Publication number
SV2017005549A
SV2017005549A SV2017005549A SV2017005549A SV2017005549A SV 2017005549 A SV2017005549 A SV 2017005549A SV 2017005549 A SV2017005549 A SV 2017005549A SV 2017005549 A SV2017005549 A SV 2017005549A SV 2017005549 A SV2017005549 A SV 2017005549A
Authority
SV
El Salvador
Prior art keywords
flap
inhibitors
useful
activating protein
lipoxygenase activating
Prior art date
Application number
SV2017005549A
Other languages
English (en)
Inventor
Johan Olof Broddefalk
Hans Fredrik Emtenäs
Malin Anita Lemurell
Kenneth Lars Granberg
Daniel Tor Pettersen
Alleyn Thomas Plowright
Ulander Lars Johan Andreas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2017005549A publication Critical patent/SV2017005549A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/50—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A COMPUESTOS DE FÓRMULA (I) (VER FORMULA) A SU UTILIDAD PARA TRATAR Y/O PREVENIR AFECCIONES CLÍNICAS INCLUYENDO ENFERMEDADES CARDIOVASCULARES (ECV), A MÉTODOS PARA SU USO TERAPÉUTICO, A COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A PROCESOS PARA PREPARAR DICHOS COMPUESTOS
SV2017005549A 2015-05-04 2017-10-20 Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap) SV2017005549A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562156424P 2015-05-04 2015-05-04

Publications (1)

Publication Number Publication Date
SV2017005549A true SV2017005549A (es) 2018-03-12

Family

ID=55910253

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005549A SV2017005549A (es) 2015-05-04 2017-10-20 Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap)

Country Status (38)

Country Link
US (5) US10183947B2 (es)
EP (2) EP3292105B1 (es)
JP (1) JP6564062B2 (es)
KR (1) KR102623474B1 (es)
CN (1) CN107646036B (es)
AR (1) AR104512A1 (es)
AU (1) AU2016258874B2 (es)
BR (1) BR112017022757B1 (es)
CA (1) CA2983668C (es)
CL (1) CL2017002660A1 (es)
CO (1) CO2017011506A2 (es)
CR (1) CR20170513A (es)
CY (2) CY1122689T1 (es)
DK (2) DK3670499T3 (es)
DO (1) DOP2017000244A (es)
EA (1) EA032221B1 (es)
ES (2) ES2760466T3 (es)
GT (1) GT201700220A (es)
HK (1) HK1245255A1 (es)
HR (2) HRP20211993T1 (es)
HU (2) HUE047445T2 (es)
IL (1) IL255069B (es)
LT (1) LT3670499T (es)
ME (1) ME03663B (es)
MX (1) MX2017013571A (es)
MY (1) MY186647A (es)
PE (1) PE20180247A1 (es)
PH (1) PH12017502112A1 (es)
PL (2) PL3670499T3 (es)
PT (2) PT3292105T (es)
RS (2) RS62729B1 (es)
SG (1) SG11201708558RA (es)
SI (2) SI3292105T1 (es)
SV (1) SV2017005549A (es)
TN (1) TN2017000458A1 (es)
TW (1) TWI718146B (es)
WO (1) WO2016177703A1 (es)
ZA (1) ZA201708189B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3292105T (pt) * 2015-05-04 2019-12-13 Astrazeneca Ab Derivados de pirazolo úteis como inibidores da proteína ativadora de 5-lipoxigenase (flap)
WO2018078097A1 (en) 2016-10-28 2018-05-03 Astrazeneca Ab Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide
CN110169969B (zh) * 2019-06-28 2022-05-27 南京医科大学 Mk571在制备预防和治疗心脏病药物中应用
CN111084775A (zh) * 2020-02-17 2020-05-01 牡丹江医学院 一种用于治疗癫痫的药物组合物
CN111419800B (zh) * 2020-04-23 2021-03-19 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 用于治疗红斑狼疮的药物制剂及其制备方法
CN111643498B (zh) * 2020-07-20 2021-05-07 黑龙江中医药大学 一种治疗肾结石的药物组合物及其用途
CN111714499B (zh) * 2020-07-27 2021-05-11 黑龙江中医药大学 一种用于治疗多囊卵巢综合征的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9400632A0 (en) 1993-04-29 1995-10-07 Zeneca Ltd Ether derivatives.
US5773422A (en) 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
CA2572750A1 (en) * 2003-09-10 2005-03-17 Anil Koul Heterobicyclic compounds as pharmaceutically active agents
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
JP2010518025A (ja) 2007-02-05 2010-05-27 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
CA2684618A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
KR20100017766A (ko) * 2007-05-10 2010-02-16 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤조-1,4-디아제핀 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 이의 용도
WO2009045700A2 (en) 2007-10-05 2009-04-09 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
PT3292105T (pt) * 2015-05-04 2019-12-13 Astrazeneca Ab Derivados de pirazolo úteis como inibidores da proteína ativadora de 5-lipoxigenase (flap)

Also Published As

Publication number Publication date
PH12017502112B1 (en) 2018-05-07
CO2017011506A2 (es) 2018-01-31
PL3292105T3 (pl) 2020-04-30
KR20180002784A (ko) 2018-01-08
RS59671B1 (sr) 2020-01-31
LT3670499T (lt) 2021-12-27
EP3670499A1 (en) 2020-06-24
IL255069A0 (en) 2017-12-31
US11001589B2 (en) 2021-05-11
HUE047445T2 (hu) 2020-04-28
ES2760466T3 (es) 2020-05-14
CN107646036A (zh) 2018-01-30
AR104512A1 (es) 2017-07-26
PL3670499T3 (pl) 2022-02-14
CA2983668C (en) 2023-06-27
BR112017022757B1 (pt) 2023-02-23
SI3670499T1 (sl) 2022-02-28
US11691978B2 (en) 2023-07-04
WO2016177703A1 (en) 2016-11-10
US20230219967A1 (en) 2023-07-13
CR20170513A (es) 2018-02-13
ES2902139T3 (es) 2022-03-25
KR102623474B1 (ko) 2024-01-09
HRP20192172T1 (hr) 2020-02-21
DK3292105T3 (da) 2019-12-09
US20210355127A1 (en) 2021-11-18
ME03663B (me) 2020-07-20
DK3670499T3 (da) 2022-01-03
JP2018514535A (ja) 2018-06-07
EP3292105A1 (en) 2018-03-14
PH12017502112A1 (en) 2018-05-07
US20200157113A1 (en) 2020-05-21
PT3292105T (pt) 2019-12-13
HRP20211993T1 (hr) 2022-04-01
EP3292105B1 (en) 2019-10-02
EP3670499B1 (en) 2021-09-29
HK1245255A1 (zh) 2018-08-24
MY186647A (en) 2021-08-03
CA2983668A1 (en) 2016-11-10
IL255069B (en) 2019-12-31
SI3292105T1 (sl) 2020-01-31
PT3670499T (pt) 2021-12-24
ZA201708189B (en) 2018-11-28
US20180237439A1 (en) 2018-08-23
BR112017022757A2 (pt) 2018-07-17
SG11201708558RA (en) 2017-11-29
PE20180247A1 (es) 2018-02-02
US20190084991A1 (en) 2019-03-21
CL2017002660A1 (es) 2018-04-13
CY1122689T1 (el) 2021-03-12
CY1125179T1 (el) 2023-03-24
DOP2017000244A (es) 2017-11-15
GT201700220A (es) 2018-12-19
EA032221B1 (ru) 2019-04-30
JP6564062B2 (ja) 2019-08-21
US10183947B2 (en) 2019-01-22
EA201792341A1 (ru) 2018-05-31
AU2016258874B2 (en) 2020-04-30
TW201713625A (zh) 2017-04-16
TN2017000458A1 (en) 2019-04-12
TWI718146B (zh) 2021-02-11
HUE056875T2 (hu) 2022-03-28
MX2017013571A (es) 2018-02-26
US10508119B2 (en) 2019-12-17
RS62729B1 (sr) 2022-01-31
AU2016258874A1 (en) 2017-12-14
NZ737672A (en) 2020-11-27
CN107646036B (zh) 2020-05-19

Similar Documents

Publication Publication Date Title
SV2017005549A (es) Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap)
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP17070706A (es) Inhibidores de bromodominio
CO2017011851A2 (es) Compuestos novedosos
CO2020003714A2 (es) Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostéricos
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
ECSP15035343A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
CR20150571A (es) Compuestos y composiciones terapéuticos
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112016001645A8 (pt) derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit
BR112016007329A2 (pt) composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica